cisplatin + irinotecan + mitomycin C

This is a combination chemotherapy regimen consisting of three cytotoxic agents—cisplatin, irinotecan, and mitomycin C. Each drug has a distinct mechanism of action targeting cancer cells: - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis by inhibiting DNA replication and transcription. - **Irinotecan** is a topoisomerase I inhibitor that prevents the religation of single-strand breaks in DNA during replication, resulting in cell death. - **Mitomycin C** is an antineoplastic antibiotic that acts as an alkylating agent; it crosslinks DNA strands under hypoxic conditions, further inhibiting DNA synthesis. The combination has been investigated primarily for advanced cancers such as kidney cancer and pleural mesothelioma. Clinical trials have shown limited efficacy in advanced kidney cancer but some response rates in mesothelioma patients[1][4][5]. The regimen’s side effects are typical for cytotoxic chemotherapy (e.g., fatigue, infection risk), but were generally considered acceptable in clinical studies[1].

Other names

IPM